New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

Ac-225-PSMA-617: another update

One of the more exciting new developments in radiopharmaceuticals for metastatic prostate cancer has been the development of alpha-particle emitters attached to PSMA ligands. We previously reported this update. … READ MORE …

When is a metastasis really metastatic today?

There is an interesting editorial commentary by Dr. Daniel George that was published just over a week ago on the UroToday web site. … READ MORE …

No pooping on PCF’s parade, please!

Some 35+ years ago, a guy called Barry Marshall and his colleague Robin Warren discovered that changes to the levels of certain bacteria in the gut led to development of ulcers … and changed everything about the way ulcers are treated. … READ MORE …

The accurate prognosis of recurrence- and metastasis-free survival

A company based on Northern Ireland called Almac Diagnostics has been working on the development of a 70-gene genetic assay (which they refer to as their Prostate Cancer Metastatic Assay) capable of projecting probability of metastasis-free survival in men treated for prostate cancer. … READ MORE …

Can the Decipher test accurately project risk for metastasis post-surgery?

A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, … READ MORE …

Time to death among men with nmCRPC by NCCN risk group

One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …